Kay Ka-Wai Li

Dr. Kay Ka-Wai Li

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2019 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
RYRui Ryan Yang
Rui Ryan Yang
ZSZhi‐Feng Shi
Zhi‐Feng Shi
ZZZhen‐Yu Zhang
Zhen‐Yu Zhang
ACAden Ka‐Yin Chan
Aden Ka‐Yin Chan
AAAbudumijiti Aibaidula
Abudumijiti Aibaidula
HNHo‐Keung Ng
Ho‐Keung Ng

14 June 2018 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
RYRui Ryan Yang
Rui Ryan Yang
AAAbudumijiti Aibaidula
Abudumijiti Aibaidula
WWWei-Wei Wang
Wei-Wei Wang
ACAden K.Y. Chan
Aden K.Y. Chan
ZSZhi-Feng Shi
Zhi-Feng Shi
HNHo-Keung NG
Ho-Keung NG

11 July 2022 in Brain Pathology
Verified
Journal Article
Open access
ELEmma Munan Liu
Emma Munan Liu
ZSZhi‐Feng Shi
Zhi‐Feng Shi
KLKay Ka-Wai Li
Kay Ka-Wai Li
TMTathiane M. Malta
Tathiane M. Malta
NCNellie Yuk‐Fei Chung
Nellie Yuk‐Fei Chung
HNHo-Keung NG
Ho-Keung NG
Telomerase reverse transcriptase (TERT) promoter (pTERT) mutation has often been described as a late event in gliomagenesis and it has been suggested as a prognostic biomarker in gliomas other than 1p19q codeleted tumors. However, the characteristics of isocitrate dehydrogenase (IDH) wild type (wt) (IDHwt), pTERTwt glioblastomas are not well known. We recruited 72 adult IDHwt, pTERTwt glioblastomas and performed methylation profiling, targeted sequencing, and fluorescence in situ hybridization (FISH) for TERT structural rearrangement and ALT (alternative lengthening of telomeres). There was no significant difference in overall survival (OS) between our cohort and a the Cancer Genome Atlas (TCGA) cohort of IDHwt, pTERT mutant (mut) glioblastomas, suggesting that pTERT mutation on its own is not a prognostic factor among IDHwt glioblastomas. Epigenetically, the tumors clustered into classic‐like (11%), mesenchymal‐like (32%), and LGm6‐glioblastoma (GBM) (57%), the latter far exceeding the corresponding proportion seen in the TCGA cohort of IDHwt, pTERTmut glioblastomas. LGm6‐GBM‐clustered tumors were enriched for platelet derived growth factor receptor alpha (PDGFRA) amplification or mutation (p = 0.008), and contained far fewer epidermal growth factor receptor (EGFR) amplification (p < 0.01), 10p loss (p = 0.001) and 10q loss (p < 0.001) compared with cases not clustered to this group. LGm6‐GBM cases predominantly showed ALT (p = 0.038). In the whole cohort, only 35% cases showed EGFR amplification and no case showed combined chromosome +7/−10. Since the cases were already pTERTwt, so the three molecular properties of EGFR amplification, +7/−10, and pTERT mutation may not cover all IDHwt glioblastomas. Instead, EGFR and PDGFRA amplifications covered 67% and together with their mutations covered 71% of cases of this cohort. Homozygous deletion of cyclin dependent kinase inhibitor 2A (CDKN2A)/B was associated with a worse OS (p = 0.031) and was an independent prognosticator in multivariate analysis (p = 0.032). In conclusion, adult IDHwt, pTERTwt glioblastomas show epigenetic clustering different from IDHwt, pTERTmut glioblastomas, and IDHwt glioblastomas which are pTERTwt may however not show EGFR amplification or +7/−10 in a significant proportion of cases. CDKN2A/B deletion is a poor prognostic biomarker in this group.

12 March 2019 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
ZSZhi‐Feng Shi
Zhi‐Feng Shi
KLKay Ka-Wai Li
Kay Ka-Wai Li
JKJohnny Sheung Him Kwan
Johnny Sheung Him Kwan
RYRui Ryan Yang
Rui Ryan Yang
AAAbudumijiti Aibaidula
Abudumijiti Aibaidula
HNHo-Keung NG
Ho-Keung NG

25 March 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
LHLiang Hong
Liang Hong
ZSZhi-Feng Shi
Zhi-Feng Shi
KLKay Ka-Wai Li
Kay Ka-Wai Li
WWWei-Wei Wang
Wei-Wei Wang
RYRui Ryan Yang
Rui Ryan Yang
HNHo-Keung Ng
Ho-Keung Ng

27 September 2022 in Brain Pathology
Verified
Journal Article
Open access
HNHo-Keung NG
Ho-Keung NG
KLKay Ka-Wai Li
Kay Ka-Wai Li
NCNellie Yuk‐Fei Chung
Nellie Yuk‐Fei Chung
JCJanice Yuen‐Tung Chan
Janice Yuen‐Tung Chan
MPManix Fung‐Man Poon
Manix Fung‐Man Poon
YMYing Mao
Ying Mao
Recurrence is a major complication of some meningiomas. Although there were many studies on biomarkers associated with higher grades or increased aggressiveness, few studies specifically examined longitudinal samples of primary meningiomas and recurrences from the same patients for molecular life history. We studied 99 primary and recurrent meningiomas from 42 patients by FISH for 22q, 1q, 1p, 3p, 5q, 6q, 10p, 10q, 14q, 18q, CDKN2A/B homozygous deletion, ALT (Alternative Lengthening of Telomere), TERT re‐arrangement, targeted sequencing and TERTp sequencing. Although NF2 mutation and 22q were well known to be aetiological events in meningiomas, we found that in these paired meningiomas, combining the two events resulted in an NF2/22q group (57 tumors from 25 patients) which were almost mutually exclusive with those cases without these two changes (42 tumors from 17 patients) for NF2/22q. No other molecular changes were totally unique to NF2/22q or non‐NF2/22q tumors. For molecular evolution, NF2/22q meningiomas had higher cytogenetic abnormalities than non‐NF2/22q meningiomas (p = 0.003). Most of the cytogenetic changes in NF2/22q meningiomas were present from the outset whereas for non‐NF2/22q meningiomas, cytogenetic events were uncommon in the primary tumors and most were acquired in recurrences. For non‐NF2/22q tumors, CDKN2A/B homozygous deletion, 1q gain, 18p loss, 3p loss, and ALT were preferentially found in recurrences. Mutations were largely conserved between primary and recurrent tumors. Phylogenetic trees showed 11/11 patients with multiple recurrent tumors had a conserved evolutionary pattern. We conclude that for molecular life history, NF2 and 22q should be regarded as a group. NF2/22q recurring meningiomas showed more cytogenetic abnormalities in the primary tumors, whereas non‐NF2/22q meningiomas showed CDKN2A/B deletion and other cytogenetic abnormalities and ALT at recurrences. Although chromosome 1p loss is a known poor prognostic marker in meningiomas, it was also associated with a shorter TBR (time between resection) in this cohort (p = 0.002).